UK researchers have begun trials for a new antibody therapy aimed at preventing the development of COVID-19 in people exposed to the novel coronavirus.
There are currently two phase 3 trials underway at University College London Hospitals’ (UCLH) vaccine research center. The trials, named Storm Chaser’ and ‘Provent’, aim to test a new antibody therapy for COVID-19. Researchers at UCLH designed the new antibody combination treatment together with the pharmaceutical company, AstraZeneca.
We know that this antibody combination can neutralize the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of Covid-19 in people who have been exposed – when it would be too late to offer a vaccine.
UCLH virologist Dr. Catherine Houlihan
Storm Chaser Begins
This new antibody therapy, called AZD7442, is a combination of two monoclonal antibodies that target the coronavirus spike protein. Thus, blocking the virus’s attachment to human cells and preventing infection. Two phase 3 trials are currently underway at UCLH to test the new treatment.
In the study Storm Chaser, researchers are testing the duration of protection provided by the treatment and its effectiveness at preventing COVID-19. While in the second trial called Provent researchers aim to test the treatment in immunocompromised individuals with exposure to the virus.
We will be recruiting people who are older or in long-term care, and who have conditions such as cancer and HIV which may affect the ability of their immune system to respond to a vaccine.
UCLH infectious diseases consultant Nicky Longley
How do Antibodies Work?
The body produced Y-shaped molecules called antibodies in response to foreign organisms such as the novel coronavirus. Advancements in science now allow scientists to create these antibodies, termed monoclonal antibodies, within laboratories. Injecting monoclonal antibodies provides an added advantage to the immune system in fighting off infections. Particularly, in patients with severe infections and compromised immune systems.
Although the US Food and Drug Administration (FDA) has approved two different antibody treatments, those are only given in mild to moderate COVID-19. With the new antibody therapy researchers aim to protect those exposed to the virus and at risk of developing COVID-19.
Researchers believe the antibody combination treatment can potentially help deal with outbreaks in nursing homes. Additionally, it can protect all those at risk of developing. a severe infection. Thus, helping save more lives in the future.
Reference:
UCLH Doses First Patient in the World in Covid-19 Antibody Trial. 25 Dec. 2020, www.uclhospitals.brc.nihr.ac.uk/news/uclh-doses-first-patient-world-covid-19-antibody-trial.
